U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.36
    -0.43 (-1.90%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.16%)
     
  • BTC-USD

    48,354.09
    +894.21 (+1.88%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

After FDA Rejection Troubled Biotech Pulls Europe Application For Bladder Cancer Drug

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Two weeks ago, Sesen Bio Inc (NASDAQ: SESN) was on the cusp of winning FDA approval for the cancer drug Vicineum.

  • It was working toward authorization in Europe. Now, with the FDA rejecting Vicineum for bladder cancer, Sesen has pulled its filing to the European Medicines Agency (EMA).

  • Read: Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News.

  • Sesen said in an SEC filing that "certain components" of the EMA are "interrelated with elements" of the FDA's decision to reject Vicineum without providing further details.

  • Sesen has halted plans to seek European approval until it has "more clarity" on the next steps in the U.S. Sesen expects to "better synchronize" the two reviews once it gets feedback from the FDA.

  • Related content: Benzinga's Full FDA Calendar

  • Price Action: SESN shares are down 3.74% at $1.03 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.